Skip to main content

The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey

This is a preview of subscription content, access via your institution.


  1. 1.

    Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18:1609–1678

    Article  PubMed  Google Scholar 

  2. 2.

    January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: A report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 64:2245–2280.

    Article  Google Scholar 

  3. 3.

    Chugh SS, Roth GA, Gillum RF, Mensah GA (2014) Global burden of atrial fibrillation in developed and developing nations. Glob Heart 9:113–119.

    Article  PubMed  Google Scholar 

  4. 4.

    Krijthe BP, Kunst A, Benjamin EJ et al (2013) Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34:2746–2751.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Healey JS, Alings M, Ha A et al (2017) Subclinical atrial fibrillation in older patients. Circulation 136:1276–1283.

    Article  PubMed  Google Scholar 

  6. 6.

    Ferro D, Loffredo L, Polimeni L, Violi F (2007) Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2:24–28.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Ogilvie IM, Newton N, Welner SA et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123:638.e4–645.e4.

    Article  Google Scholar 

  8. 8.

    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Larsen TB, Skjøth F, Nielsen PB et al (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189.

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Prisco D, Ageno W, Becattini C et al (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12:387–406.

    Article  PubMed  Google Scholar 

  12. 12.

    Borghi C, Paolillo S, Cicero AFG et al (2017) New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation. J Hypertens 35:689–695.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Hsu JC, Maddox TM, Kennedy KF et al (2016) Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk. JAMA Cardiol 1:55.

    Article  PubMed  Google Scholar 

  14. 14.

    Kjerpeseth LJ, Ellekjær H, Selmer R et al (2017) Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 73:1417–1425.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Gülker J-E, Kröger K, Kowall B et al (2018) Increasing use of anticoagulants in Germany and its impact on hospitalization for intracranial bleeding. Circ Cardiovasc Qual Outcomes 11:e004470.

    Article  PubMed  Google Scholar 

  16. 16.

    Volterrani M, Iellamo F, Alberto C et al (2018) NOAC in “real world” patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. 2 Intern Emerg Med. (in press)

    Article  PubMed  Google Scholar 

  17. 17.

    Huisman MV, Rothman KJ, Paquette M et al (2017) The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol 69:777–785.

    Article  PubMed  Google Scholar 

Download references


The authors report no specific funding in relation to the preparation of this paper.

Author information



Corresponding author

Correspondence to Giuseppe Mulè’.

Ethics declarations

Conflict of interest

The author(s) declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animal performed by any of the authors.

Informed consent

No informed consent is required.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mulè’, G., Carollo, C., Guarneri, M. et al. The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey. Intern Emerg Med 13, 1005–1007 (2018).

Download citation


  • Thromboprophylaxis
  • Landscape Change
  • Non-valvular Atrial Fibrillation (NVAF)
  • Norwegian Prescription Database
  • Prolonged Electrocardiographic Monitoring